Actavis Raises Bid For Pliva; Will Barr Follow?
This article was originally published in The Pink Sheet Daily
Executive Summary
Actavis has increased its bid for the Croatian generic drug maker to roughly $2.5 bil., trumping Barr's $2.3 bil. offer.
You may also be interested in...
Actavis Warning Letter Adds Fuel To Pliva Takeover Battle
Barr says FDA warning letter demonstrates Actavis’ inability to integrate acquisitions like Pliva.
Actavis Warning Letter Adds Fuel To Pliva Takeover Battle
Barr says FDA warning letter demonstrates Actavis’ inability to integrate acquisitions like Pliva.
Two Pliva ANDAs Approved Following Lifting of FDA Hold
The Croatian firm will launch generic azithromycin imminently, having resolved manufacturing issues at its Zagreb plant.